Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Reaction formation

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    17 result(s) found for: Reaction formation. Displaying page 1 of 1.
    EudraCT Number: 2015-001761-11 Sponsor Protocol Number: 300488 Start Date*: 2015-08-31
    Sponsor Name:The Department of Cardiothoracic and Vascular Surgery, Aarhus University Hospital
    Full Title: Lymphatic dysfunction as a cause of calcium channel blocker oedema in post-menopausal women
    Medical condition: Calcium channel antagonist induced peripheral edema in post-menopausal women. We hypothesize that this condition is partly due to impaired lymphatic function in these patients.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004867 10067033 Drug side effect LLT
    18.0 100000004867 10034570 Peripheral edema LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2008-005075-10 Sponsor Protocol Number: CL08002 Start Date*: 2008-10-01
    Sponsor Name:BioCis Pharma Oy
    Full Title: Double-blind, vehicle-controlled, two-phase, single centre Phase I/IIa study with topical twice daily doses of 5% cis-urocanic acid to investigate pharmacokinetics, safety, tolerability and efficac...
    Medical condition: Chronic mild to moderate atopic dermatitis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-004728-14 Sponsor Protocol Number: TCP25-001 Start Date*: 2022-03-10
    Sponsor Name:Xinnate AB
    Full Title: A Three-part, Phase I Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of Topical Doses of TCP-25 in Healthy Male and Female Volunteers with Epidermal Suction Blister Wounds and in...
    Medical condition: TCP-25 gel targets both bacteria and inflammation, aspects common to many wounds and is being developed for a range of wound healing indications including prevention and treatment of infection and ...
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001054-96 Sponsor Protocol Number: 000013/BT Start Date*: 2020-03-19
    Sponsor Name:Bone Therapeutics S.A.
    Full Title: Phase IIb, Placebo-Controlled, Randomized, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Allogeneic Osteoblastic Cells (ALLOB) Single Implantation in Tibial Fracture
    Medical condition: Tibial fracture considered at risk of DU/NU (based on the combination of risk factors documented to be associated with increased proportion of DU/NU).
    Disease: Version SOC Term Classification Code Term Level
    20.0 10022117 - Injury, poisoning and procedural complications 10043827 Tibia fracture PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Ongoing) DE (Prematurely Ended) HU (Prematurely Ended) PL (Prematurely Ended) ES (Ongoing) CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-011017-24 Sponsor Protocol Number: ADNC-0726 Start Date*: 2009-08-03
    Sponsor Name:LFB Biotechnologies
    Full Title: A Phase II, open-label, randomised, dose-finding study to compare the efficacy (in terms of clearance of RhD-positive RBCs) and safety of LFB-R593, a monoclonal anti-RhD antibody, vs Rhophylac®, a ...
    Medical condition: Prophyllaxis against RhD isoimmunisation during pregnancy (anti-D prophylaxis) Treatment of RhD negative individuals after incompatible transfusions with blood components containing RhD-positive r...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019513 Hemolytic disease of fetus or newborn, due to isoimmunization LLT
    9.1 10044360 Transfusion with incompatible blood LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-005979-16 Sponsor Protocol Number: PrOvAS001 Start Date*: 2013-04-29
    Sponsor Name:Instituto de Investigación Sanitaria La Fe
    Full Title: PREECLAMPSIA OF PREVENTION IN PATIENTS THROUGH ovodonation aspirin in early gestation
    Medical condition: PREECLAMPSIA
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-000657-36 Sponsor Protocol Number: 46934 Start Date*: 2015-06-22
    Sponsor Name:University Medical Center Groningen
    Full Title: Open-label crossover trial to investigate the efficacy of treatments in apomorphine-induced skin reactions
    Medical condition: Parkinson's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-004222-34 Sponsor Protocol Number: IMCgp100-102 Start Date*: 2016-03-07
    Sponsor Name:Immunocore Limited
    Full Title: A Phase 1/2 Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 using the Intra-patient Escalation Dosing Regimen in Patients with Advanced Uveal Melanoma
    Medical condition: Advanced Uveal Melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061252 Intraocular melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-020329-42 Sponsor Protocol Number: CORTISONE Start Date*: 2010-01-25
    Sponsor Name:AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE
    Full Title: EFFECTS OF PREVENTIVE TREATMENT WITH STEROIDS ON COAGULATION DYSFUNCTION INDUCED BY EXTRACORPOREAL CIRCULATION
    Medical condition: All patients were candidates for cardiac surgery intervention in extracorporeal circulation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007541 SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002190-10 Sponsor Protocol Number: UCDCRC/20/03 Start Date*: 2021-02-05
    Sponsor Name:University College Dublin
    Full Title: Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG)
    Medical condition: Coagulopathy of COVID-19 appears to afflict approximately 20% of patients with severe COVID-19 and is associated with need for critical care and death. COVID-19 coagulopathy is characterized by ele...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2022-001780-27 Sponsor Protocol Number: HTA-HG5-04 Start Date*: Information not available in EudraCT
    Sponsor Name:Holostem Terapie Avanzate s.r.l.
    Full Title: OPEN-LABEL, UNCONTROLLED, CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AUTOLOGOUS FIBRIN-CULTURED EPIDERMAL GRAFTS CONTAINING EPIDERMAL STEM CELLS GENETICALLY MODIFIED FOR RESTORATION OF E...
    Medical condition: Inherited Epidermolysis Bullosa (EB) is a group of rare, devastating genetic disorders characterized by structural and mechanical fragility of skin and mucosal membranes, impairing the patient’s qu...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10014989 Epidermolysis bullosa PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-003450-22 Sponsor Protocol Number: P-105-303 Start Date*: 2022-03-08
    Sponsor Name:AlloVir, Inc.
    Full Title: Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial, with Cross-Over, of Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standar...
    Medical condition: AdV infection in pediatric and adult allo HCT recipients receiving standard of care
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10060931 Adenovirus infection PT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-002549-39 Sponsor Protocol Number: Ponatinib-1501 Start Date*: 2020-12-07
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lympho...
    Medical condition: acute lymphoblastic leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) CZ (Completed) NL (Prematurely Ended) IT (Prematurely Ended) PL (Prematurely Ended) PT (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-001758-14 Sponsor Protocol Number: 201677 Start Date*: 2015-12-18
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients with Giant Cell Arteritis
    Medical condition: Giant Cell Arteritis (GCA)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10047065 - Vascular disorders 10047116 Vascular inflammations HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) BG (Prematurely Ended) HU (Prematurely Ended) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-003874-42 Sponsor Protocol Number: CP-4-006 Start Date*: 2017-09-04
    Sponsor Name:OPKO Biologics Ltd.
    Full Title: A phase 3, open-label, randomized, multicenter, 12 months, efficacy and safety study of weekly mod-4023 compared to daily genotropin® therapy in pre-pubertal children with growth hormone deficiency
    Medical condition: Growth hormone deficiency in pre-pubertal children
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) BG (Completed) FR (Completed) PL (Completed) ES (Ongoing) GR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000650-11 Sponsor Protocol Number: HEP002 Start Date*: 2014-09-15
    Sponsor Name:Promethera Biosciences
    Full Title: A prospective, open label, multicountry, efficacy and safety study of several infusions of HepaStem in Urea Cycle Disorders pediatric patients.
    Medical condition: The urea cycle disorders are inborn errors of metabolism that affect the transfer of nitrogen into urea. There are seven disorders to be investigated: carbamoylphosphate synthetase I deficiency [CP...
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004861 10013373 Disorders of urea cycle metabolism LLT
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) FR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-005573-21 Sponsor Protocol Number: A4021004 Start Date*: 2007-01-26
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A TWO-ARM RANDOMIZED OPEN LABEL PHASE 2 STUDY OF CP-751,871 IN COMBINATION WITH EXEMESTANE VERSUS EXEMESTANE ALONE AS FIRST LINE TREATMENT FOR POSTMENOPAUSAL PATIENTS WITH HORMONE RECEPTOR POSITIVE...
    Medical condition: Hormone receptor positive advanced breast cancer in postmenopausal women.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) NL (Temporarily Halted) GB (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 13 12:37:13 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA